Corcept Therapeutics (CORT)
NASDAQ: CORT
· Real-Time Price · USD
70.97
-0.91 (-1.27%)
At close: May 01, 2025, 12:00 PM
-1.27% (1D)
| Bid | 70.82 |
| Market Cap | 7.49B |
| Revenue (ttm) | 675.04M |
| Net Income (ttm) | 140.69M |
| EPS (ttm) | 1.23 |
| PE Ratio (ttm) | 57.7 |
| Forward PE | 20.33 |
| Analyst | Strong Buy |
| Ask | 71.06 |
| Volume | 244,528 |
| Avg. Volume (20D) | 1,585,593 |
| Open | 71.59 |
| Previous Close | 71.88 |
| Day's Range | 69.26 - 71.61 |
| 52-Week Range | 23.02 - 117.33 |
| Beta | 0.14 |
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 14, 2004
Employees 500
Stock Exchange NASDAQ
Ticker Symbol CORT
Website https://www.corcept.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CORT stock is "Strong Buy." The 12-month stock price forecast is $146, which is an increase of 105.74% from the latest price.
Stock ForecastsNext Earnings Release
Corcept Therapeutics is scheduled to release its earnings on May 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+109.08%
Corcept Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
2 months ago
-5.55%
Corcept Therapeutics shares are trading lower after the company reported worse-than-expected Q4.
